Metabolic Impact of Rapamycin (Sirolimus) and B-Estradiol Using Mouse Embryonic Fibroblasts As a Model for Lymphangioleiomyomatosis

Overview

Journal Lung

Specialty Pulmonary Medicine

Date 2017 Jun 4

PMID 28577037

Authors

Katherine M Marsh

David Schipper

Alice S Ferng

Kitsie Johnson

Julia Fisher

Shannon Knapp

Destiny Dicken

Zain Khalpey

Affiliations

Soon will be listed here.

Abstract

Introduction: Lymphangioleiomyomatosis (LAM) is a rare, progressive cystic lung disease that predominantly affects women of childbearing age. Exogenous rapamycin (sirolimus) has been shown to improve clinical outcomes and was recently approved to treat LAM, whereas estrogen (E) is implicated in disease progression. No consistent metabolic model currently exists for LAM, therefore wild-type mouse embryonic fibroblasts (MEF +/+) and TSC2 knockout cells (MEF -/-) were used in this study as a model for LAM.

Methods: Oxygen consumption rates (OCR) and redox potential were measured to determine metabolic state across control cells, MEF +/+ and -/- cells treated with rapamycin (Rapa), and MEF +/+ and -/- cells treated with E. An XF96 extracellular flux analyzer from Seahorse Bioscience was used to measure OCR, and a RedoxSYS™ ORP was used to measure redox potential.

Results: OCR of MEF -/- cells treated with rapamycin (MEF -/- Rapa) versus MEF -/- control were significantly lower across all conditions. The static oxidation reduction potential of the MEF -/- Rapa group was also lower, approaching significance. The coupling efficiency and ratio of ATP-linked respiration to maximum respiration were statistically lower in MEF -/- Rapa compared to MEF +/+ Rapa. There were no significant metabolic findings across any of the MEF cells treated with E. MEF -/- control cells versus MEF +/+ control cells were not found to significantly differ.

Conclusion: MEF cells are thought to be a feasible metabolic model for LAM, which has implications for future pharmacologic and biologic testing.

References

Gu X, Yu J, Ilter D, Blenis N, Henske E, Blenis J . Integration of mTOR and estrogen-ERK2 signaling in lymphangioleiomyomatosis pathogenesis. Proc Natl Acad Sci U S A. 2013; 110(37):14960-5. PMC: 3773757. DOI: 10.1073/pnas.1309110110. View

Taveira-DaSilva A, Moss J . Clinical features, epidemiology, and therapy of lymphangioleiomyomatosis. Clin Epidemiol. 2015; 7:249-57. PMC: 4396456. DOI: 10.2147/CLEP.S50780. View

Yu J, Robb V, Morrison T, Ariazi E, Karbowniczek M, Astrinidis A . Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells. Proc Natl Acad Sci U S A. 2009; 106(8):2635-40. PMC: 2637277. DOI: 10.1073/pnas.0810790106. View

Yu J, Astrinidis A, Howard S, Henske E . Estradiol and tamoxifen stimulate LAM-associated angiomyolipoma cell growth and activate both genomic and nongenomic signaling pathways. Am J Physiol Lung Cell Mol Physiol. 2003; 286(4):L694-700. DOI: 10.1152/ajplung.00204.2003. View

Krymskaya V, Goncharova E . PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects. Cell Cycle. 2009; 8(3):403-13. PMC: 3718392. DOI: 10.4161/cc.8.3.7555. View

Zhang H, Bajraszewski N, Wu E, Wang H, Moseman A, Dabora S . PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J Clin Invest. 2007; 117(3):730-8. PMC: 1784000. DOI: 10.1172/JCI28984. View

Sun Q, Chen X, Ma J, Peng H, Wang F, Zha X . Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc Natl Acad Sci U S A. 2011; 108(10):4129-34. PMC: 3054028. DOI: 10.1073/pnas.1014769108. View

Corradetti M, Inoki K, Bardeesy N, DePinho R, Guan K . Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev. 2004; 18(13):1533-8. PMC: 443516. DOI: 10.1101/gad.1199104. View

Finlay G . The LAM cell: what is it, where does it come from, and why does it grow?. Am J Physiol Lung Cell Mol Physiol. 2004; 286(4):L690-3. DOI: 10.1152/ajplung.00311.2003. View

10.

Li C, Lee P, Sun Y, Gu X, Zhang E, Guo Y . Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med. 2014; 211(1):15-28. PMC: 3892971. DOI: 10.1084/jem.20131080. View

11.

von Ranke F, Zanetti G, Silva J, Araujo Neto C, Godoy M, Souza C . Tuberous Sclerosis Complex: State-of-the-Art Review with a Focus on Pulmonary Involvement. Lung. 2015; 193(5):619-27. DOI: 10.1007/s00408-015-9750-6. View

12.

York B, Lou D, Panettieri Jr R, Krymskaya V, Vanaman T, Noonan D . Cross-talk between tuberin, calmodulin, and estrogen signaling pathways. FASEB J. 2005; 19(9):1202-4. DOI: 10.1096/fj.04-3142fje. View

13.

Uhlenbrock K, Weiwad M, Wetzker R, Fischer G, Wittinghofer A, Rubio I . Reassessment of the role of FKBP38 in the Rheb/mTORC1 pathway. FEBS Lett. 2009; 583(6):965-70. DOI: 10.1016/j.febslet.2009.02.015. View

14.

Niu H, Wang J, Li H, He P . Rapamycin potentiates cytotoxicity by docetaxel possibly through downregulation of Survivin in lung cancer cells. J Exp Clin Cancer Res. 2011; 30:28. PMC: 3065416. DOI: 10.1186/1756-9966-30-28. View

15.

Schieke S, Phillips D, McCoy Jr J, Aponte A, Shen R, Balaban R . The mammalian target of rapamycin (mTOR) pathway regulates mitochondrial oxygen consumption and oxidative capacity. J Biol Chem. 2006; 281(37):27643-52. DOI: 10.1074/jbc.M603536200. View

16.

Ferrans V, Yu Z, Nelson W, Valencia J, Tatsuguchi A, Avila N . Lymphangioleiomyomatosis (LAM): a review of clinical and morphological features. J Nippon Med Sch. 2000; 67(5):311-29. DOI: 10.1272/jnms.67.311. View

17.

Shackelford D, Shaw R . The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer. 2009; 9(8):563-75. PMC: 2756045. DOI: 10.1038/nrc2676. View

18.

Zhang H, Cicchetti G, Onda H, Koon H, Asrican K, Bajraszewski N . Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J Clin Invest. 2003; 112(8):1223-33. PMC: 213485. DOI: 10.1172/JCI17222. View

19.

Gupta N, Vassallo R, Wikenheiser-Brokamp K, McCormack F . Diffuse Cystic Lung Disease. Part I. Am J Respir Crit Care Med. 2015; 191(12):1354-66. PMC: 5442966. DOI: 10.1164/rccm.201411-2094CI. View

20.

Ramanathan A, Schreiber S . Direct control of mitochondrial function by mTOR. Proc Natl Acad Sci U S A. 2010; 106(52):22229-32. PMC: 2796909. DOI: 10.1073/pnas.0912074106. View